Contact Us

•health professionals

TEXT SIZE

Bringing the Experts to You

'This is the most exciting ASH meeting that I've been to, and I've been a member for over 25 years.' Morie Gertz, MD Mayo Clinic The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2008 annual meeting of the American Society of Hematology in San Francisco, California. We hope you will find this material informative and useful.

print     share |

01.04.09   Dr. Anderson - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition December 6-9, 2008 San Francisco, CA
	Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, Massachusetts U.S.A. Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Gertz - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition December 6-9, 2008 in San Francisco, CA and
	Morie Gertz, MD Mayo Clinic Rochester, Minnesota USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Rajkumar - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition December 6-9, 2008 San Francisco, CA
	Dr. Vincent Rajkumar Mayo Clinic Rochester, Minnesota USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Van Ness - ASH 2008 - Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma
	Brian Van Ness, PhD University of Minnesota Institute of Human Genetics Minneapolis, Minnesota USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Morgan - ASH 2008 - Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients
	Gareth Morgan, MD Section of Haemato-Oncology The Institute of Cancer Research London, United Kingdom Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Morgan - ASH 2008 - High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma
	Gareth Morgan, MD Section of Haemato-Oncology The Institute of Cancer Research London, United Kingdom Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Munshi - ASH 2008 - Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients
	Nikhil Munshi, MD Dana-Farber Cancer Institute Boston, Massachusetts USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Reece - ASH 2008 - The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Ontario Canada Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Goldschmidt - ASH 2008 - Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma
	Hartmut Goldschmidt, MD Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen Heidelberg, Germany Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Beksac - ASH 2008 - HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)
	Meral Beksac, MD Ankara University School of Medicine Ankara, Turkey Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
	William Bensinger, MD Fred Hutchinson Cancer Research Center Seattle, Washington U.S.A. Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Knop - ASH 2008 - Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
	Stephan Knop, MD University Hospital Würzburg Würzburg, Germany

---

01.04.09   Dr. Kumar - ASH 2008 - Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma
	Shaji Kumar, MD Mayo Clinic Rochester, Minnesota U.S.A.

---

01.04.09   Dr. Kumar - ASH 2008 - Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
	Shaji Kumar, MD Mayo Clinic Rochester, Minnesota U.S.A.

---

01.04.09   Dr. Kumar - Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study
	Shaji Kumar, MD Mayo Clinic Rochester, Minnesota USA

---

01.04.09   Dr. Lokhorst - ASH 2008 - Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)
	Henk M. Lokhorst, MD University Medical Center Utrecht Utrecht, Netherlands Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Palumbo - ASH 2008 - Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results
	Antonio Palumbo, MD Divisione di Ematologia dell'Università di Torino A.O.U. San Giovanni Battista Torino, Italy Member,IMF Board of Scientific Advisors

---

01.04.09   Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
	Pieter Sonneveld, MD, PhD Erasmus Medical Center Rotterdam, Netherlands Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Hajek - ASH 2008 - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance
	Roman Hajek, MD University Hospital Brno Brno, Czech Republic Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Harousseau - ASH 2008 - Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone
	Jean-Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Palumbo - ASH 2008 - A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
	Antonio Palumbo, MD Divisione di Ematologia dell'Università di Torino A.O.U. San Giovanni Battista Torino, Italy Member,IMF Board of Scientific Advisors

---

01.04.09   Dr. Palumbo - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients
	Antonio Palumbo, MD Divisione di Ematologia dell'Università di Torino A.O.U. San Giovanni Battista Torino, Italy Member,IMF Board of Scientific Advisors

---

01.04.09   Dr. Wijermans - ASH 2008 - Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study
	Pierre Wijermans, MD Haga Hospital The Hague, Netherlands

---

01.04.09   Dr. Avigan - Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma
	David Avigan, MD Beth Israel Deaconess Medical Center Boston Massachusetts USA

---

01.04.09   Dr. Barlogie - ASH 2008 - Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5
	Bart Barlogie, MD, PhD University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy Little Rock, Arkansas USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Bladé - ASH 2008 - Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial
	Joan Bladé, MD Hospital Clinic Barcelona, Spain Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Cavo - ASH 2008 - Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma; Up-Front Response Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities
	Michele Cavo, MD Bologna University School of Medicine Seragnoli Institute of Hematology and Medical Oncology Bologna, Italy

---

01.04.09   Dr. Harousseau - ASH 2008 - Velcade-Dexamethasone versus VAD as Induction Treatment Prior to ASCT in Newly Diagnosed MM. Updated Results of the IFM2005/01 Trial.
	Jean-Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Jakubowiak - ASH 2008 - Initial Treatment with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)
	Andrzej Jakubowiak, MD University of Michigan Cancer Center Ann Arbor, Michigan U.S.A.

---

01.04.09   Dr. Lonial - ASH 2008 - A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
	Sagar Lonial, MD Winship Cancer Institute Emory University Atlanta, Georgia U.S.A. Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Niederwieser - ASH 2008 - Overview of the European Bone Marrow Transplant Group (EBMT)
	Dietger W. Niederwieser, MD University of Leipzig Leipzig, Germany

---

01.04.09   Dr. Dispenzieri - ASH 2008 - Primary Therapy with Bortezomib—the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02
	Angela Dispenzieri, MD Mayo Clinic Rochester, Minnesota USA

---

01.04.09   Dr. Landau - ASH 2008 - Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response
	Heather Landau, MD Memorial Sloan-Kettering Cancer Center New York, New York U.S.A.

---

01.04.09   Dr. Rajkumar - ASH 2008 - Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
	Dr. Vincent Rajkumar Mayo Clinic Rochester, Minnesota USA

---

01.04.09   Dr. Morgan - ASH 2008 - CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
	Gareth Morgan, MD Section of Haemato-Oncology The Institute of Cancer Research London, United Kingdom Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Petrucci - ASH 2008 - Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial
	Maria Teresa Petrucci, MD Università La Sapienza Rome, Italy

---

01.04.09   Dr. Reece - ASH 2008 - Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Ontario Canada Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Reece - ASH 2008 - Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Ontario Canada Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Weber - ASH 2008 - Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience
	Donna Weber, MD M.D. Anderson Cancer Center Houston Texas USA

---

01.04.09   Dr. Jagannath - ASH 2008 - Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, New York USA Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Jakubowiak - ASH 2008 - Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
	Andrzej Jakubowiak, MD University of Michigan Cancer Center Ann Arbor, Michigan USA

---

01.04.09   Dr. Kaufman - ASH 2008 - First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma
	Jonathan Kaufman, MD Emory University School of Medicine Winship Cancer Institute Atlanta Georgia USA

---

01.04.09   Dr. Knop - ASH 2008 - Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial
	Stephan Knop, MD University Hospital Würzburg Würzburg, Germany

---

01.04.09   Dr. Lacy - ASH 2008 - Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma
	Martha Q. Lacy, MD Mayo Clinic Rochester, Minnesota U.S.A.

---

01.04.09   Dr. Lonial - ASH 2008 - A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
	Sagar Lonial, MD Winship Cancer Institute Emory University Atlanta, Georgia USA

---

01.04.09   Dr. Miki - ASH 2008 - KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts
	Hirokazu Miki, MD Tokushima Uiveristy HospitalTokushima, Japan

---

01.04.09   Dr. Pozzi - ASH 2008 - Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease
	Samantha Pozzi, MD Dana-Farber Cancer Institute Jerome Lipper Multiple Myeloma Disease CenterBoston Massachusetts USA 2009 IMF Grant Recipient

---

01.04.09   Dr. San Miguel - ASH 2008 - Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Santo - ASH 2008 - AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β
	Loredana Santo, MD Dana-Farber Cancer Institute Boston, Massachusetts USA 2009 IMF Grant Recipient

---

01.04.09   Dr. Vij - ASH 2008 - Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
	Ravi Vij, MD Washington University School of Medicine Saint Louis, Missouri USA

---

01.04.09   Dr. Vogl - ASH 2008 - Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma
	Dan T. Vogl, MD Abramson Cancer Center, University of Pennsylvania School of Medicine Myeloma Program Philadelphia, Pennsylvania USA

---

01.04.09   Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma
	Jeffrey A. Zonder, MD Karmanos Cancer Institute Detroit, Michigan

---

01.04.09   Dr. Ludwig - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
	Heinz Ludwig, MD Wilhelminenspital der Stadt Wein Vienna, Austria Member, IMF Board of Scientific Advisors

---

01.04.09   Dr. Morgan - ASH 2008 - Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation
	Gareth Morgan, MD Section of Haemato-Oncology The Institute of Cancer Research London, United Kingdom Member, IMF Board of Scientific Advisors

---

01.20.09   Multiple Myeloma: Finding Your Way Through the Treatment Maze - Selecting the Best Treatment in the Era of Novel Agents
	Audiocast of the IMF Super Friday Program at the 50th ASH Annual Meeting and Exposition

---